ea0029p171 | Bone & Osteoporosis | ICEECE2012
, Zgliczynski W.
Primary hyperparathyroidism (PHPT) is often associated with reduced bone mineral density (BMD). An open-labeled, prospective trial was conducted to determine whether denosumab 60 mg subcutaneously given every 6 months, maintains or improves BMD in patients with PHPT.Six patients had symptomatic PHPT and met surgical guidelines however refused surgery, and twelve patients had mild PHPT, asymptomatic except low BMD. The primary outcome index, BMD, was meas...